Anastrozole/Fulvestrant/Gefitinib neoadjuvant therapy of estrogen receptor positive breast cancer patients: tumor core biopsies
Summary:
Analysis of pre and post (3 wk) tumor core biopsies of postmenopausal women with ER+, HER2- breast cancer (BC) in neoadjuvant trial of anastrozole and fulvestrant with/without gefitinib. Results provide insight into mechanisms of resistance and inhibition of hormone receptors targeted in BC therapy.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Massarweh S, Tham YL, Huang J, Sexton K et al. A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat 2011 Oct;129(3):819-27. PMID: 21792626
